Showing results (1001-1010 of 8,876) with videos related to

Sort By:
Pageof 888
BJU International|October 13, 2006
Challenges in a larger bladder replacement with cell-seeded and unseeded small intestinal submucosa grafts in a subtotal cystectomy modelYuanyuan Zhang, Dominic Frimberger, Earl Y Cheng, et al.
BJU International|September 19, 2006
A prospective observational trial of pelvic floor muscle training for female stress urinary incontinenceJames R Balmforth, Jill Mantle, John Bidmead, et al.
BJU International|September 19, 2006
Comparison of right and left laparoscopic live donor nephrectomyMark D Kay, Nicholas Brook, Monika Kaushik, et al.
BJU International|September 19, 2006
Injectable polydimethylsiloxane for treating incontinence in children with the exstrophy-epispadias complex: long-term resultsTariq Burki, Rizwan Hamid, Phillip G Ransley, et al.
BJU International|September 19, 2006
The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancerLutz Trojan, Florian Rensch, Martin Voss, et al.
BJU International|August 2, 2008
Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of applicationAntonella Giannantoni, Ettore Mearini, Michele Del Zingaro, et al.
BJU International|July 24, 2008
Spontaneous contractions of the pig urinary bladder: the effect of ATP-sensitive potassium channels and the role of the mucosaHironobu Akino, Christopher R Chapple, Neil McKay, et al.
BJU International|July 24, 2008
Comparison of fesoterodine and tolterodine in patients with overactive bladderChristopher R Chapple, Philip E Van Kerrebroeck, Klaus-Peter Jünemann, et al.
BJU International|July 24, 2008
Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetineRidwan Shabsigh, Donald L Patrick, David L Rowland, et al.
BJU International|June 15, 2006
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castrationChris J Tyrrell, Peter Iversen, Teuvo Tammela, et al.
Pageof 888